CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 11 enrolled
Drug / intervention
Exendin-9,39 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04459338
NCT04459338Phase 3Completed
CompareCT.gov

A Dose-response Study Examining the Contribution of GLP-1 Receptor Signaling to Glucagon-stimulated Insulin Secretion

Adrian Vella·interventional·Posted Jul 7, 2020·Updated Jun 9, 2023

In Brief

A Phase 3 clinical trial evaluating Exendin-9,39 and Saline for Healthy. Completed, enrolled 11 participants across 1 site.

Detailed Summary

The GLP-1 receptor (GLP1R) gene is found on the beta cells of the pancreas. Its role is in the control of blood sugar level by enhancing insulin secretion from the pancreas after eating a meal. The purpose of this research study is to evaluate the role of GLP1R in the response to elevated glucagon concentrations.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Timeline

Phase 3CompletedFinished
202120222023202420252026
First PostedJul 7, 2020
Enrollment StartMar 4, 2021
Primary CompletionJun 14, 2022
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 6.0 years ago

Interventions

Exendin-9,39biological

Exendin-9,39 is a competitive antagonist of GLP-1 actions at the GLP-1 receptor

Salineother

Placebo comparator